Japanese eye company Santen has released positive top-line data for the first Phase III trial of its sirolimus-based uveitis treatment.
The trial, dubbed SAKURA Study 1, is evaluating intravitreal injections of sirolimus at three doses in 347 patients with non-infectious...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
